Listar por autor "Albanell, J."
Mostrando ítems 1-4 de 4
-
A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study
Alba-Conejo, Emilio
; Chacón, J. L.; Lluc, A.; Antón, A.; Estévez, L.; Cirauqui, B.; Carrasco, E.; Calvo, L.; Seguí, M.A.; Ribelles, Nuria; Álvarez, R.; Sánchez-Muñoz, Alfonso; Sánchez, R.; Lopez Garcia-Asenjo, J.A.; Rodriguez-Martin, C.; Escudero, M.J.; Albanell, J.[et al.] (Springer, 2012-10)
Abstract Chemotherapy remains as the only systemic treatment option available for basal-like breast cancer (BC) patients. Preclinical models and several phase II studies suggested that platinum salts are active drugs in ... -
Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER1) node-negative breast cancer
Albanell, J.; González, A.; Ruiz-Borrego, M; Alba-Conejo, Emilio; García-Saenz, J.A.; Corominas, J. M.; Burgues, O.; Furio, V.; Rojo, A.; Palacios, J.; Bermejo, B.; Martínez-García, M.; Limón, L.M.; Sánchez-Muñoz, Alfonso; Martín, M.; Tusquets, I.; Rojo, R.; Colomer, R.; Faull, F.; Lluch, A.[et al.] (Elsevier, 2012-03)
This study examined the impact of the Recurrence Score (RS) in Spanish breast cancer patients and explored the associations between clinicopathological markers and likelihood of change in treatment recommendations. Patients ... -
Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER).
Albanell, J.; Martínez-García, M.; Ramos-Boyero, Manuel; O'Connor, Miriam; De-la-Cruz-Merino, Luis; Santaballa-Bertrán, Ana; Martínez-Jáñez, Noelia; Moreno-Antón, Fernando; Fernández, Isaura; Alarcón, Jesús Damián; Virizuela-Echaburu, Javier Antonio; De-la-Haba-Rodríguez, Juan Rafael; Sánchez- Rovira, P; González-Cortijo, Lucía; Margelí, Mireia; Sánchez-Muñoz, Alfonso; Antón, A.; Casas, María Isabel; Bezares, Susana; Rojo, Federico[et al.] (Elsevier, 2022)
Background: The potential benefit of adding palbociclib to fulvestrant as first-line treatment in hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative endocrine-sensitive advanced breast ... -
Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy.
Santonja, Ángela; Sánchez-Muñoz, Alfonso; Lluch, Ana; Chica Parrado, María del Rosario; Albanell, J.; Chacón, José Ignacio; Antolín, Silvia; Jerez-Aragonés, José Manuel; De la Haba, Juan; De Luque, Vanessa; Fernández-De-Sousa, Cristina Elisabeth; Vicioso-Recio, Luis Prudencio; Plata-Fernández, Yéssica; Ramírez-Tortosa, César; Álvarez-Pérez, Martína; Llácer, Casilda; Zarcos-Pedrinaci, Irene; Carrasco, Eva; Caballero, Rosalía; Martín, Miguel; Alba-Conejo, Emilio[et al.] (Impact Journals, 2018-05-29)
Triple negative breast cancer (TNBC) is a heterogeneous disease with distinct molecular subtypes that differentially respond to chemotherapy and targeted agents. The purpose of this study is to explore the clinical ...